Kathryn Sykes | Vice President Research And Product Development
Calviri Inc

Kathryn Sykes, Vice President Research And Product Development, Calviri Inc

Kathryn Sykes has decades of experience inventing and developing innovative molecular, genetic and biochemical technologies to manipulate the immune system towards better health. Before joining Calviri, she grew the labs at HealthTell and served as V.P. of Research. Previously, she was a professor in the School of Life Sciences at the Biodesign Institute at Arizona State University. At the University of Texas Southwestern Medical School, she pursued technologies that became the basis of a Texas biotechnology company, ultimately acquired by Macrogenics. Dr. Sykes received her B.S. in Biology and Economics from Duke University and her Ph.D. in Biochemistry and Genetics from Duke University Medical Center.

Appearances:



Pre-congress Workshops, April 6 @ 10:00

WORKSHOP B (FULL DAY): ANIMAL HEALTH

AM: SCIENTIFIC ADVANCEMENTS IN THE COMPANION ANIMAL CANCER VACCINE SPACEWorkshop Leader: Philip J. Bergman
  • Overcoming current limitations in selecting immunogenic neoantigens
  • Bridging the gap between human and animal cancer: translational studies of a polyvalent cancer preventative vaccine
  • Personalized autologous cancer vaccine for cats & dogs
  • Development of an animal health vaccine using gene-based checkpoint inhibitors
  • The safety of an adjuvanted autologous cancer vaccine platform in canine cancer patients
  • From treating veterinary cancers to launching a first-in-human clinical trial

Day 2, April 8 @ 09:10

RNA frameshift errors provide new product opportunities against cancer

last published: 17/Feb/20 09:15 GMT
last published: 17/Feb/20 09:15 GMT
last published: 17/Feb/20 09:15 GMT
last published: 17/Feb/20 09:15 GMT
last published: 17/Feb/20 09:15 GMT
last published: 17/Feb/20 09:15 GMT
last published: 17/Feb/20 09:15 GMT
last published: 17/Feb/20 09:15 GMT
last published: 17/Feb/20 09:15 GMT
last published: 17/Feb/20 09:15 GMT
last published: 17/Feb/20 09:15 GMT

back to speakers